Stratagene loses jury verdict to Invitrogen over infringement of US 4,981,797

Stratagene, no stranger to patent infringement contests, lost a jury verdict to Invitrogen on a patent concerning E. coli cell products.

The jury determined that Invitrogen's 4,981,797 patent is valid and that Strategene willfully infringed between 1997 and 2001.

In a separate matter, PubPat is seeking to contest through re-examination the validity of claims of WARF's US 5,843,780 and 6,200,806 concerning embryonic stem cells.